Supernus Pharmaceuticals (SUPN) Accounts Payables (2011 - 2026)

Supernus Pharmaceuticals (SUPN) has 16 years of Accounts Payables data on file, last reported at $101.2 million in Q1 2026.

• Accounts Payables for Q1 2026 came in at $101.2 million, up 31.67% year-over-year; the trailing twelve-month figure through Mar 2026 was $101.2 million (up 31.67% YoY), and the FY2025 annual result was $107.8 million, up 41.19% from the prior year.
• Accounts Payables eased to $101.2 million in Q1 2026 per SUPN's latest filing, from $107.8 million in the prior quarter.
• Over five years, Accounts Payables peaked at $133.0 million in Q2 2022 and troughed at $75.8 million in Q3 2024.
• A 5-year average of $91.7 million and a median of $86.4 million in 2024 frame the typical range for Accounts Payables.
• The sharpest annual moves came in 2022 and 2023: Accounts Payables soared 66.26% in 2022, then plunged 37.56% in 2023.
• A 5-year view of Accounts Payables shows it stood at $96.3 million in 2022, then fell by 17.41% to $79.6 million in 2023, then fell by 4.04% to $76.4 million in 2024, then soared by 41.19% to $107.8 million in 2025, then declined by 6.08% to $101.2 million in 2026.
• Business Quant data shows SUPN's Accounts Payables at $101.2 million in Q1 2026, $107.8 million in Q4 2025, and $108.6 million in Q3 2025.